OPKO HEALTH, INC.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Large accelerated filer
State of Incorporation
DE
Business Address
4400 BISCAYNE BLVD., MIAMI, FL, 33137
Mailing Address
4400 BISCAYNE BLVD., MIAMI, FL, 33137
Phone
305-575-4181
Fiscal Year End
1231
EIN
752402409
Financial Overview
FY2025
-$10.30M
Net Income
$2.20B
Total Assets
$834.76M
Total Liabilities
$1.56B
Stockholders' Equity
$-0.01
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 4 Insider stock transaction report | March 20, 2026 | View on SEC |
| 4 Insider stock transaction report | March 20, 2026 | View on SEC |
| 3 Initial insider ownership report | March 20, 2026 | View on SEC |
| 8-K Current report of material events | March 19, 2026 | View on SEC |
| 10-K Annual financial report | February 26, 2026 | View on SEC |
| 8-K Current report of material events | February 26, 2026 | View on SEC |
| 4 Insider stock transaction report | November 21, 2025 | View on SEC |
| 4 Insider stock transaction report | November 20, 2025 | View on SEC |
| 4 Insider stock transaction report | November 19, 2025 | View on SEC |
| 4 Insider stock transaction report | November 18, 2025 | View on SEC |
Annual Reports
10-K
February 26, 2026
- Total revenue increased by 5% to $985 million in 2024, driven by strong Pharmaceutical segment performance.
- Pharmaceutical segment revenue grew by 12% to $450 million, with Rayaldee sales up 15% to $280 million.
Insider Trading
BUY
1 insiders
1 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.